Cargando…

Antibody‐mediated enzyme formation: Its legacy at age fifty‐four

Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, com...

Descripción completa

Detalles Bibliográficos
Autores principales: Strom, Roberto, Celada, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286546/
https://www.ncbi.nlm.nih.gov/pubmed/34693572
http://dx.doi.org/10.1002/jmr.2931
_version_ 1784748036495245312
author Strom, Roberto
Celada, Franco
author_facet Strom, Roberto
Celada, Franco
author_sort Strom, Roberto
collection PubMed
description Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, commenting 16 original figures selected to be re‐printed in AMEF's Legacy. We, the reviewers, started by revisiting our own “insider's” experience of discovery, and followed by considering all results, our own and of members of other AMEF Labs. We had planned to conclude the review by correlating the various AMEF mutants to a detailed knowledge of the consensus betaGal structure. However, we became aware of several “robust” papers, published between 1989 and 2014, by authors outside of AMEF Labs. We familiarly called this surge: “The Second Wave” and adorned it with a doodle in Hokusai style. We were thrilled and happy to take them on board and properly examined their data. A team of this second wave had imagined unique uses for AMEF, and new doors to modern biotechnology. Another one had used AMEF as Tool and Marker to attain high levels of crystallography, solving puzzles of conformation, and ultimate structure. Together, they doubled our motivation to review AMEF. Serendipity gives us back the pleasure of finding, a treat at any age.
format Online
Article
Text
id pubmed-9286546
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92865462022-07-19 Antibody‐mediated enzyme formation: Its legacy at age fifty‐four Strom, Roberto Celada, Franco J Mol Recognit Review Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, commenting 16 original figures selected to be re‐printed in AMEF's Legacy. We, the reviewers, started by revisiting our own “insider's” experience of discovery, and followed by considering all results, our own and of members of other AMEF Labs. We had planned to conclude the review by correlating the various AMEF mutants to a detailed knowledge of the consensus betaGal structure. However, we became aware of several “robust” papers, published between 1989 and 2014, by authors outside of AMEF Labs. We familiarly called this surge: “The Second Wave” and adorned it with a doodle in Hokusai style. We were thrilled and happy to take them on board and properly examined their data. A team of this second wave had imagined unique uses for AMEF, and new doors to modern biotechnology. Another one had used AMEF as Tool and Marker to attain high levels of crystallography, solving puzzles of conformation, and ultimate structure. Together, they doubled our motivation to review AMEF. Serendipity gives us back the pleasure of finding, a treat at any age. John Wiley and Sons Inc. 2021-10-24 2021-12 /pmc/articles/PMC9286546/ /pubmed/34693572 http://dx.doi.org/10.1002/jmr.2931 Text en © 2021 The Authors. Journal of Molecular Recognition published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review
Strom, Roberto
Celada, Franco
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title_full Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title_fullStr Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title_full_unstemmed Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title_short Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
title_sort antibody‐mediated enzyme formation: its legacy at age fifty‐four
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286546/
https://www.ncbi.nlm.nih.gov/pubmed/34693572
http://dx.doi.org/10.1002/jmr.2931
work_keys_str_mv AT stromroberto antibodymediatedenzymeformationitslegacyatagefiftyfour
AT celadafranco antibodymediatedenzymeformationitslegacyatagefiftyfour